| Ytd | -24.82% | |
| 1y | 198.63% |
| Open | 53.70 | Prev Close | 53.80 | Low | 52.26 | High | 53.70 | Mkt Cap | 3.01B |
| Vol | 169.29K | Avg Vol | 705.12K | EPS | -1.57 | P/E | -33.33 | Forward P/E | -25.81 |
| Beta | -1.43 | Short Ratio | 7.32 | Inst. Own | 96.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 47.54 | 200-d Avg | 52.64 | 1yr Est | 105.10 |
GPCR News
[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 por
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk an
Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Sc
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinic
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking T
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on meta
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targ
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centere
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., L
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight lo
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101
